Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.81 |
| ▸ | HPGD | P15428 | 5/20 | 0.81 |
| ▸ | POLH | Q9Y253 | 5/20 | 0.81 |
| ▸ | TP53 | P04637 | 4/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.81 |
| ▸ | MAOA | P21397 | 4/20 | 0.81 |
| ▸ | MAOB | P27338 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apigenin SCHEMBL19428 | 0.89 | KMT2A (1.00) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL5083245 | 0.89 | KMT2A (1.00) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL29351464 | 0.89 | KMT2A (1.00) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL29968480 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL1658882 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL29872582 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL31477961 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL29458838 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL30544810 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 | |
| Apigenin SCHEMBL31168790 | 0.88 | KMT2A (0.97) | MEN1ALDH1A1KMT2ACYP1B1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965173-A | Compounds and methods for treating estrogen receptor-related disorders | HENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-103965172-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-102018698-B | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-07-02 | — | — | CN | disclosed |
| CN-103755673-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-04-30 | — | — | CN | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | MEN1 3679/4885ALDH1A1 1811/4885KMT2A 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.